Current Cosmetics Ingredients Challenges: How to Navigate a Newly Painted Landscape
December 11, 2025 | 2:00PM–3:30PM ET | Live Webinar
Overview
Gain insight into current cosmetics ingredient challenges, including state law bans and reporting requirements, litigation issues, claims and promotional guidelines, and tariff and supply chain considerations. In addition, learn about best practices for studies of ingredients that may have functional use(s), and how to substantiate ingredient safety.
Speakers
José Alberto Campos Vargas
Read Bio
Partner, Garrigues
Biography
JOSÉ ALBERTO has over 23 years’ experience advising clients on their foreign trade and customs transactions. He has extensive experience in international trade and customs matters, ranging from strategic planning to litigation involving both Mexican matters as well as international proceedings in connection with free trade agreements and tax issues arising from these cases.
He also has a wealth of experience advising clients on their operations in connection with highly regulated products and services, whether regulated by the Ministry of Health or the Ministry of Agriculture, Farming, Rural Development, Food and Fishing or other similar authorities, as regards their import, manufacturing, storage, marketing, transport processes, etc.
Daniel Dwyer
Read Bio
Partner, Kleinfeld, Kaplan & Becker, LLP
Biography
DAN DWYER is a partner at Kleinfeld Kaplan & Becker LLP, who has built a nationally recognized practice in FDA law, advertising law, and related matters. He has expertise in food, drug, cosmetic and medical device safety issues, clinical trials, labeling and advertising claim substantiation, sales and marketing practices, good manufacturing practices, FDA inspections, recalls, corporate compliance programs, Food Safety Modernization Act (FSMA) requirements, and prescription drug exclusivity. He serves a diverse range of organizations in the food, cosmetic, pharmaceutical, medical device, and consumer product industries.
Frederick A. Stearns
Read Bio
Partner, Keller and Heckman LLP
Biography
FREDERICK A. STEARNS is a partner in Keller and Heckman LLP’s Washington, DC, office. Rick’s practice involves a wide range of issues facing manufacturers of prescription and over-the-counter drugs, medical devices, dietary supplements, foods, and cosmetics. He helps product manufacturers evaluate the need for marketing approval from FDA, pursue appropriate clearance when necessary, and address regulatory compliance issues with marketed products (including OTC drug monographs, product labeling and promotion, and current good manufacturing practices). Rick works with clients to respond to FDA enforcement activities, navigate the interrelationship of the patent laws and the FDA drug approval process, communicate with Agency officials, and develop innovative strategies to deal with evolving FDA regulatory requirements. In addition, Rick has worked with numerous companies to conduct FDA due diligence reviews, both for internal control purposes and as part of product line or corporate acquisitions. He is a frequent speaker at conferences on the legal issues involving the regulation of drugs, medical devices, food, cosmetics, and dietary supplements. Rick received his BS in applied and engineering physics from Cornell University and his JD with honors from The George Washington University Law School.
Shuo Yu
Read Bio
Managing Consultant, Environment & Health, Ramboll
Biography
DR. YU is a Managing Consultant in Health Sciences at Ramboll’s Arlington office, with 14 years of experience in product safety assessment, ecological risk assessment, and human health risk assessment of a variety of chemical substances. She has provided technical evaluations and advice in support of pre-market approvals and regulation compliance for various industrial and consumer products, under regulatory frameworks such as US Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), US Food and Drug Administration (FDA), US Toxic Substances Control Act (TSCA), EU Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), and European Medicines Agency (EMA). Dr. Yu has also conducted a spectrum of human health and ecological risk assessments on contaminated sites for public and private clients from US and abroad, including database management, multi-pathway human and ecological exposure modeling, biomonitoring data analysis and modeling, bioavailability and bioaccumulation analysis, (eco)toxicology data evaluation, and development of site-specific risk-based benchmarks for various human populations and ecological receptors.
Moderated By Kayla J. Cristales
Read Bio
Associate, Haynes and Boone LLP
Biography
KAYLA CRISTALES is a senior associate in the FDA Regulatory and Compliance Practice Group at Haynes and Boone, LLP. Haynes Boone is an Am Law 100 firm, with over 650 lawyers in 19 offices around the world, providing services for more than 40 major legal practices. Kayla’s practice focuses on transactional and regulatory matters for FDA-regulated clients, with particular expertise in cosmetics and personal care products. For example, Kayla regularly counsels cosmetic and OTC drug brand owners, retailers, and distributors in connection with packaging and label compliance and claim-related risk assessments; substantiation reviews; product classification analyses; manufacturing, development, commercialization, and supply agreement negotiation; and advertising, marketing, and other promotional communications, among many other areas involving the wide range of often complex and overlapping federal and state laws and regulations governing cosmetics, drugs, and medical devices, respectively. Kayla also has substantial experience in conducting diligence, negotiating key contractual terms, assisting with post-closing transitions, and other key elements of mergers and acquisitions involving FDA-regulated parties, as well as in advising issuers and underwriters on material regulatory matters and related considerations in connection with securities offerings and SEC filings in the life sciences space.
